CoChat
Sign Up
Cited by 152Growth Hormone and Insulin-like Growth FactorsHypothalamic control of reproductive hormonesPituitary Gland Disorders and Treatments

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Estrogen receptor blockade with tamoxifen diminishes growth hormone secretion in boys: evidence for a stimulatory role of endogenous estrogens during male adolescence.

Metzger, D L, Kerrigan, J R·1994·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jcem.79.2.8045971
Open this paper in CoChat — free account

Abstract

The increase in GH production during the male adolescent growth spurt has been attributed to both androgen and estrogen receptor-mediated processes. To evaluate the role of endogenous estrogens in the control of GH secretion, we administered the estrogen receptor antagonist tamoxifen to 10 late pubertal males. Blood samples were obtained for GH determination at 10-min intervals on 2 occasions during the last 24 h of a 4-day course of either tamoxifen or placebo. Waveform-specific, multiple parameter deconvolution analysis was employed to assess GH secretory and elimination dynamics. Estrogen receptor blockade resulted in a significant (P < 0.05) diminution in mean 24-h serum GH concentrations, from 3.9 +/- 1.0 (placebo; mean +/- SEM) to 2.7 +/- 0.6 micrograms/L (tamoxifen). This was associated with a significant (P < 0.01) decline in the GH production rate [237 +/- 55 vs. 155 +/- 33 micrograms/L GH distribution volume (Lv).24 h]. Furthermore, this reduction in GH secretion was the result of significant decreases in both the maximal GH secretory rate (0.46 +/- 0.08 vs. 0.34 +/- 0.06 microgram/Lv.min; P < 0.01) and, to a smaller degree, GH secretory burst number (16 +/- 1 vs. 14 +/- 1/24 h; P < 0.05). There was also a trend toward reduced mass of GH secreted per burst (13.3 +/- 2.5 vs. 10.3 +/- 2.0 micrograms/Lv; P = 0.06). No significant alterations in either GH elimination t1/2 or GH secretory burst half-duration were observed during estrogen receptor antagonism. Tamoxifen tr…

Overview

Integrity signals

Registry

Crossref · 10.1210/jcem.79.2.8045971

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Flagged first, then by citations

Show all 34 references

Cited by

Sorted by citations

Items 101–152 of 152

Related

See all

Metadata

Authors
Metzger, D. L., & Kerrigan, J. R.
Affiliations
University of Virginia (US)
ORCID
Metzger, D L
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
1994-08
Volume
79
Issue
2
Pages
513-518
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jcem.79.2.8045971
OpenAlex
W2026707439
Cited by
152
References
34
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 1 · 2014: 5 · 2013: 2
FWCI
4.10
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Commons - East Tennessee State University (East Tennessee State University) (submittedVersion)
Funders
  • National Institutes of Health (5k08hd000926-03)
  • National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK 07642, T32DK007642)
  • National Center for Research Resources (RR 00847, M01RR000847)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (K08 HD00926)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
Keywords
growth hormone secretion, tamoxifen, estrogen receptor antagonism, endogenous estrogen, male adolescence, pubertal growth spurt, somatotropic axis, insulin-like growth factor I, boys, luteinizing hormone, testosterone, estradiol, IGF binding protein-3, deconvolution
MeSH terms
Adolescent, Estrogens, Humans, Insulin-Like Growth Factor I, Male, Puberty, Receptors, Estrogen, Growth Hormone, Tamoxifen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review